ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Disease Activity"

  • Abstract Number: 0221 • ACR Convergence 2025

    A Multimodal Intervention Improves the Quantity and Quality of Disease Activity Measures Collection in a Multi-Centered National Rheumatoid Arthritis Network

    Grant Cannon1, Beth Wallace2, Deana Lazaro3, Pascale Schwab4, Paul Monach5, Ankoor Shah6, Gail Kerr7, Andreas Reimold8, Joshua Baker9, Gary Kunkel10, Katherine Wysham11, Liron Caplan12, John Richards13, Aleksander Lenert14, Andrew Jones15, Ted Mikuls16, Maria I. ("Maio") Danila17, Bryant England16, Brian Sauer18, Jorge Rojas19 and Isaac Smith20, 1University of Utah and Salt Lake City VA, Salt Lake City, UT, 2Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, 3VA New York Harbor Healthcare system, Short Hills, NJ, 4VA Portland and Oregon Health & Science University, Portland, OR, 5VA Boston Healthcare System, Boston, MA, 6Duke University, Durham, NC, 7Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, 8Dallas VA Medical Center, Dallas, TX, 9University of Pennsylvania, Philadelphia, PA, 10University of Utah and George E Wahlen VAMC, Salt Lake City, UT, 11VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, 12Rocky Mountain Regional VAMC, Aurora, CO, 13Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, 14University of Iowa, Iowa City, IA, 15VA Saint Louis and Washington University, Saint Louis, 16University of Nebraska Medical Center, Omaha, NE, 17University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL, 18Salt Lake City VA/University of Utah, Salt Lake City, UT, 19VA Puget Sound Health Care System, Seattle, WA, 20Duke University Hospital, Durham, NC

    Background/Purpose: Clinical guidelines recommend the use of disease activity measures (DAMs) in rheumatoid arthritis (RA) management. Measurement of DAMs is also a critical component of…
  • Abstract Number: 2564 • ACR Convergence 2025

    An illustration-based patient-reported outcome measure reveals concealed symptoms in patients with rheumatoid arthritis and the factor contributing to the discrepancy between patient and evaluator global assessments

    Mie Fusama1, Hideko Nakahara2, Megumi Okada3, Kayoko Sakagami4, Ikuyo Noguchi5, Harumi Matsumura6, Hiroaki Ito4, Kosaku Oda5, Yoshitaka Shinto3, Kenshi Higami6, Satomi Higami6 and Tetsuya Tomita7, 1Kansai University of International Studies, Miki, Japan, 2Osaka Yukioka College of Health Science, Ibaraki, Osaka, Japan, 3Shinto Orthopaedics and Rheumatology Clinic, Osaka, Japan, 4Infusion Clinic, Osaka, Japan, 5Oda Orthopedic Surgery Rheumatology Clinic, Nishinomiya, Japan, 6Higami Clinic of Rheumatology and Diabetology, Kashihara, Japan, 7Morinomiya University of Medical Sciences, Osaka, Japan

    Background/Purpose: RA patients frequently encounter challenges in effectively communicating their symptoms to medical professionals. Recently, the “Okomarigoto Sheet” (OS), an illustration-based patient-reported outcome measure for…
  • Abstract Number: 2292 • ACR Convergence 2025

    Safety and Humoral Response to Recombinant Herpes Zoster Vaccine in immunosuppressed Sjögren’s Disease Patients: Results From a Double-Blinded Placebo-Controlled Study

    Sandra G Pasoto1, Talita Ribeiro2, Nadia Emi Aikawa3, Ana C Medeiros-Ribeiro1, Bruno Borges2, Andre Franco4, Henrique Silva2, Eloisa Bonfa5 and Clovis Artur Silva6, 1Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, 2Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, Brazil, 3Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, São Paulo, Brazil, 4Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Sao Paulo, Brazil, 5Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, 6University of São Paulo, São Paulo, São Paulo, Brazil

    Background/Purpose: Immunosuppressed Sjögren’s disease (SjD) patients are at increased risk of herpes zoster (HZ). Despite this vulnerability, data on safety and immunogenicity of the recombinant…
  • Abstract Number: 1973 • ACR Convergence 2025

    Evaluating the Impact of Clinical Pharmacist Integration on Patient Care Outcomes in a Private Rheumatology Clinic

    Madana Kamineni1, Janelle Vircks1, Jessica Lynton1, Clarisse Purvis1 and Brittany Panico2, 1Optum, Gilbert, AZ, 2Summit Rheumatology, Gilbert, AZ

    Background/Purpose: Existing data demonstrate that clinical pharmacist integration in rheumatology clinics improves provider satisfaction, patient outcomes, medication adherence, and RAPID-3 (Routine Assessment of Patient Index…
  • Abstract Number: 1495 • ACR Convergence 2025

    Comparing the 0-10 Physician Global Assessment Scale to Categorical Disease Activity States among Pediatric Patients with SLE

    Livie Timmerman1, Melissa Mannion2 and Emily Smitherman2, 1University of Alabama at Birmingham, Gardendale, AL, 2University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: The Physician Global Assessment (PGA) is used to measure disease activity on a 0–10 scale for many pediatric rheumatic conditions. However, the thresholds at…
  • Abstract Number: 1332 • ACR Convergence 2025

    Mid‐Infrared Spectroscopy for Enhanced Diagnosis of Rheumatic Diseases

    Gilad Halpert1, Yair Dankner2, Eri Govrin1, Abdulla Watad3, Omer Gendelman1, Shlomo Segev1, Yehuda Shoenfeld1 and Howard Amital1, 1Sheba Medical Center, Ramat Gan, Israel, 2Shenkar College of Engineering and Design, Ramar Gan, Israel, 3Tel Hashomer Medical Center, Ramat Gan, Israel

    Background/Purpose: Spectral analysis of liquid biopsies has recently emerged as a promising, non-invasive approach to improve the diagnosis of various pathologies. Our objective was to…
  • Abstract Number: 1028 • ACR Convergence 2025

    Enhanced Assessment of Psoriatic Arthritis Disease Progression Using cDAPSA plus the Contrast of Patient Reported Pain and Global Assessment versus Joint Counts

    Ning Meng1, Scott Zeger2, John Miller1, Uzma Haque3, Thomas Grader-Beck4, Laura Hummers5, Clifton Bingham1, Ami Shah5, Ana-Maria Orbai6 and Ji Soo Kim7, 1Johns Hopkins University, Baltimore, MD, 2Johns Hopkins Biostatistics, Baltimore, MD, 3Johns Hopkins School of Medicine, Baltimore, MD, 4Johns Hopkins, Reisterstown, MD, 5Johns Hopkins Rheumatology, Baltimore, MD, 6Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 7Johns Hopkins, Baltimore, MD

    Background/Purpose: The clinical Disease Activity in Psoriatic Arthritis (cDAPSA) score is widely used to assess PsA disease activity and its trajectory. cDAPSA sums four measures:…
  • Abstract Number: 0777 • ACR Convergence 2025

    Development of a Disease Activity Index for the Assessment of VEXAS Syndrome (VEXAS-DAI)

    Kevin Byram1, Herman Mann2, Danielle Hammond3, Sinisa Savic4, Yohei Kirino5, Carmelo Gurnari6, Mael Heiblig7, Thibault Comont8, Arsène Mekinian9, Mrinal Patnaik10, Lachelle D. Weeks11, Gary Ho12, Onima Chowdhury13, Adam Al-Hakim14, Scott Goldberg15, Marcela ferrada16, Sophie georgin-Lavialle17, Peter Grayson18, Emma Groarke19, Bhavisha Patel20, Megan Sullivan21, Sarah A. Buckley22, Bryan G. harder22, Sandra Goble22, Matthew Koster10 and David Beck23, 1Vanderbilt University Medical Center, Nashville, TN, 2Institute of Rheumatology, Praha 2, Czech Republic, 3The University of Texas MD Anderson Cancer Center, Houston, TX, 4University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, 5Yokohama City University Graduate School of Medicine, Yokohama, Japan, 6Department of Biomedicine and Prevention, University of Rome Tor Vergata and Translational Hematology and Oncology Research Department, Taussig Cancer Center, Cleveland Clinic, Clevland, OH, Rome, Italy, 7Lyon-Sud Hospital, Hospices Civils de Lyon, Paris and Université Claude Bernard, Lyon, France, 8Centre Hospitalier Universitaire Toulouse Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France, 9Department of Internal Medicine, Inflammation-Immunopathology-Biotherapy Department (DMU i3), Saint-Antoine University Hospital, 75012 Paris, France, Paris, France, 10Mayo Clinic, Rochester, MN, 11Dana Farber Cancer Institute, Boston, MA, 12New York University Grossman School of Medicine, VA New York Harbor Health Care System, Brooklyn, NY, 13Oxford University Hospitals’ NHS Foundation Trust and Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom, 14University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine,, Leeds, United Kingdom, 15New York University Grossman School of Medicine, Brooklyn, NY, 16University of Maryland, Bethesda, MD, 17Sorbonne university, Tenon hospital, DMU3ID, CEREMAIA, ERN RITA, Paris, France, 18National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD, 19National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD, 20National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Beltsville, MD, 21Mayo Clinic Arizona, Scottsdale, AZ, 22Sobi Inc., Waltham, MA, 23Center for Human Genetics and Genomics, NYU Grossman School of Medicine. Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine. Department of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, New York, NY, USA, New York, NY

    Background/Purpose: VEXAS syndrome is a recently described severe disease characterized by a complex overlap of inflammatory and hematologic features. Due to the severity and refractory…
  • Abstract Number: 0441 • ACR Convergence 2025

    Charting the Course of Worsening: Utilizing Standard Outcomes to Define Worsening for Pathophysiological Insights into RA

    Charis Meng1, Caci Julia2, Kelsey Gripp2, Deanna Jannat-Khah1, Yvonne Lee3, Susan J. Bartlett4, Clifton Bingham5 and Vivian Bykerk1, 1Hospital for Special Surgery, New York, NY, 2Hospital for Special Surgery, New York, 3Northwestern University, Chicago, IL, 4McGill University, Beaconsfield, QC, Canada, 5Johns Hopkins University, Baltimore, MD

    Background/Purpose: RA disease worsening contributes to joint damage and cardiovascular disease. While measures of improvement are established in RA, we do not have uniform definitions…
  • Abstract Number: 0222 • ACR Convergence 2025

    Evaluating the Barriers and Facilitators for Collecting and Documenting Rheumatoid Arthritis Disease Activity Measures Using a Rheumatology Provider Survey

    Isaac Smith1, Linda Tovar2, Michael Battistone2, Andrea Barker3, Bryant England4, Ankoor Shah5, Joshua Baker6, Katherine Wysham7, Beth Wallace8, Ted Mikuls4, Deanna Lazaro9, Pascale Schwab10, Paul Monach11, Gail Kerr12, Andreas Reimold13, Gary Kunkel2, Liron Caplan14, John Richards15, Aleksander Lenert16, Andrew Jones17, Maria I. ("Maio") Danila18, Brian Sauer19, Jorge Rojas20 and Grant Cannon21, 1Duke University Hospital, Durham, NC, 2Salt Lake City VA, Salt Lake City, UT, 3Salt Lake City VA, Cottonwood Heights, UT, 4University of Nebraska Medical Center, Omaha, NE, 5Duke University, Durham, NC, 6University of Pennsylvania, Philadelphia, PA, 7VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, 8Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, 9VA New York Harbor Healthcare System, Brooklyn, NY, 10Oregon Health & Science University, Portland, OR, 11VA Boston Healthcare System, Boston, MA, 12Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, 13Dallas VA Medical Center, Dallas, TX, 14University of Colorado, Denver, CO, 15Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, 16Iowa Carver College of Medicine, Iowa City, IA, 17VA Saint Louis and Washington University, Saint Louis, 18University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL, 19Salt Lake City VA/University of Utah, Salt Lake City, UT, 20VA Puget Sound Health Care System, Seattle, WA, 21University of Utah and Salt Lake City VA, Salt Lake City, UT

    Background/Purpose: Collection of disease activity measures (DAMs) is a key component of high-quality care for rheumatoid arthritis (RA) patients. This study surveyed rheumatology providers at…
  • Abstract Number: 2456 • ACR Convergence 2025

    Predictors of Real-World Remission in Patients with SLE Initiating Belimumab in the USA

    Aarat M Patel1, Renee L. Gennarelli2, Temitope Bello2, Ali Bonakdar2 and Karen Worley3, 1GSK, US Medical Affairs, Durham, NC, 2Cencora, Real-World Evidence, Conshohocken, PA, 3GSK, Global Real-World Evidence & Health Outcomes Research, Collegeville, PA

    Background/Purpose: The Definition Of Remission in SLE (DORIS) criteria were developed to align SLE remission definitions.1,2 Post hoc analyses of clinical trial data demonstrated that…
  • Abstract Number: 2290 • ACR Convergence 2025

    Patterns and Predictors of Clinical Improvement in Patients with Sjögren’s Disease: A Longitudinal Analysis of ESSDAI and ESSPRI Improvements

    Alejandro Gómez Gómez1, Sergio H. Martínez Mateu2, Jose Luis Tandaipan3, Monica Fernandez Castro4, Guillermo gonzalez5, Sheila Melchor-Díaz6, Miren Uriarte Ecenarro7, Raúl Menor Almagro8, Paloma Vela Casasempere9, Beatriz Paredes-Romero10, Judit Font-Urgelles11, Paula Estrada-Alarcón12, Sara Manrique-Arija13, Mª Angeles Blazquez Cañamero14, Clara Moriano15, Juan José Alegre-Sancho16, Marina Rodríguez López17, Marta López18, Gema Bonilla19, Rafaela Ortega-Castro20, Sara Maria Rojas Herrera21, Ignacio Braña22, Lilian López-Núñez23, Javier Narváez24, Jose Rosas Gómez de Salazar25, Ruben D. López-Sánchez26, Carles Galisteo Veiga27, Javier Martínez-Ferrin28, Jose Javier Pérez Venegas29, Guadalupe Manzano-Canabal30, Cilia Peralta-Ginés31, Lara Sánchez Bilbao32, José Andrés Román Ivorra33, Rafael Cáliz-Cáliz34, Belén Serrano-Benavente35, Sabela Fernández-Aguado36, Natalia Boix- Martí37, Eric Kirkegaard-Biosca38, Iago Alvarez Saez39, Ares Selles-Rius40, Maribel Pérez41, Juan Cañete42, Sara Marsal1 and Jose Luis Andreu43, 1Vall d'Hebron Hospital Research Institute, Rheumatology Research Group, Barcelona, Spain, 2IMIDomics, Barcelona, Spain, 3Rheumatology. Hospital Universitario de la Santa Creu i Sant Pau, Barcelona, Spain, 4PUERTA DE HIERRO HOSPITAL, Madrid, Spain, 5Hospital Universitario de A Coruña, A Coruña, Spain, 6Hospital Universitario 12 de Octubre, Rheumatology, Madrid, Madrid, 7Hospital Universitario La Princesa, Madrid, Spain, 8Department of Rheumatology, Hospital de Jerez, Spain, Puerto De Santa María, Spain, 9Hospital General Universitario Alicante, Alicante, Comunidad Valenciana, Spain, 10Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, San Sebastian de los Reyes, Spain, 11Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 12Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, 13Hospital Regional Universitario Málaga, Malaga, Spain, 14Hospital Ramon y Cajal, Madrid, Spain, 15Hospital León, LEON, Castilla y Leon, Spain, 16Hospital Universitario Doctor Peset, Valencia, Spain, 17Complejo Hospitalario Universitario de Santiago, Rheumatology, Santiago de Compostela., Santiago de Compostela, Spain, 18Complex Hospitalari Universitari Moisés Broggi, Barcelona, Spain, 19Hospital Universitario La Paz, Rheumatology, Madrid, Madrid, Spain, 20Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, 21Hospital de Mérida, Rheumatology, Badajoz, Badajoz, Spain, 22Hospital Universitario Central de Asturias, Oviedo, Spain, 23Hospital Son Llatzer, Rheumatology, Palma de Mallorca, Palma de Mallorca, Spain, 24Hospital Universitario de Bellvitge, Barcelona, Spain, 25Hospital Marina Baixa, PALMA DE MALLORCA, Spain, 26Hospital Universitario de Gran Canaria Dr. Negrín, Gran Canaria, Spain, 27Hospital Parc Taulí, Rheumatology, Sabadell, Sabadell, Spain, 28Hospital Universitario Virgen de la Arrixaca, Rheumatology, Murcia, Murcia, Spain, 29Virgen Macarena University Hospital, Sevilla, Spain, Sevilla, Spain, 30Hospital Virgen de la Concha (Zamora), Zamora, Spain, 31Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, 32Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, 33Hospital Universitari i Politècnic La Fe, Valencia, Spain, 34Hospital Universitario Virgen de las Nieves, Rheumatology, Granada, Granada, Spain, 35Hospital Gregorio Marañon, Madrid, Spain, 36Hospital Universitario de Pontevedra, Pontevedra, Spain, 37Hospital Univetsitari Vall d'Hebron, Rheumatology Department, Barcelona, Spain, 38Hospital Univetsitari Vall d'Hebron, Ophthalmology Department, Barcelona, Spain, 39Hospital Univetsitari Vall d'Hebron, Maxilofacial Surgery Department, Barcelona, Spain, 40Rheumatology Research Group, Vall d'Hebron University Hospital, Barcelona, Spain, 41IMIDomics, Barcelona, Barcelona, Spain, 42Rheumatology Department, Hospital Clínic and IDIBAPS, Barcelona, Spain, Barcelona, Spain, 43Hospital Universitario Puerta de Hierro, Majadahonda, Spain

    Background/Purpose: Assessing clinical improvements in Sjögren's Disease (SjD) is challenging. Our objective was to describe patterns of improvement in SjD using ESSDAI and ESSPRI indices…
  • Abstract Number: 1831 • ACR Convergence 2025

    Distinct Proteomic Signature Predicts Post-MMF Withdrawal Flares in Systemic Lupus Erythematosus Patients

    Christian Wright1, Miles Smith2, Rufei Lu2, Catriona Wagner3, Aleksandra Bylinska2, Carla Guthridge2, Nicholas Domingez2, Susan Macwana2, Wade DeJager4, Marci Beel5, Joan Merrill6, Eliza Chakravarty2, Ellen Goldmuntz7, Study Team ALE06 Clinical8, Judith James2 and Joel Guthridge2, 1University of Oklahoma Health Sciences Center, Oklahoma City, OK, 2Oklahoma Medical Research Foundation, Oklahoma city, OK, 3Oklahoma Medical Research Foundation, Santa Cruz, CA, 4Oklahoma Medical Research Foundation, Oklahoma City, 5Oklahoma Medical Research Foun, Oklahoma City, OK, 6Oklahoma Medical Research Foundation, Oklahoma City 73104, OK, 7NIAID/ NIH, Washington, DC, 8Autoimmunity Center of Excellence, Oklahoma City, OK

    Background/Purpose: : Systemic Lupus Erythematosus (SLE) follows a characteristic relapsing-remitting course with unpredictable flares interspersed with periods of relative quiescence. Mycophenolate mofetil (MMF) has emerged…
  • Abstract Number: 1491 • ACR Convergence 2025

    Feasibility of Extrarenal Systemic Lupus Erythematosus Disease Modification in GLADEL 2.0, a Latin American Cohort

    julián Barahona-correa1, Santiago Bernal-Macías2, Daniel Fernandez3, Óscar Muñoz2, Lucia Hernández4, Erika Susana Palacios Santillan5, Laura Maurelli6, Paula Alba7, Veronica Saurit8, Lucila Garcia9, María Emilia Sattler10, Maria Constanza Bertolaccini11, Marina Laura Micelli12, Graciela Gomez13, Micaela A. Cosatti14, Ana Carolina Ralle15, Joaquín Martinez Serventi16, Ana Silva17, ODIRLEI MONTICIELO18, Ángela Luzia Branco Pinto Duarte19, Laíssa Cristina Alves Alvino20, Eduardo Borba21, Eloisa Bonfa21, Edgard dos Reis-Neto22, Iris Guerra Herrera23, Milena Mimica24, Gustavo Aroca Martínez25, Lorena Gómez Escorcia26, Carlos Alberto Cañas27, Gerardo Quintana-Lopez28, Carlos Toro-Gutierrez29, José Maximiliano Martínez Pérez30, Reyna Elizabeth Sánchez-Briones31, Mario Pérez Cristóbal32, Eduardo Martin-Nares33, Yaneli Juarez-Vicuña34, Ignacio García-Valladares35, Rodrigo Ortiz Hernández36, Jorge Antonio Esquivel Valerio37, Maria Isabel Acosta38, Astrid Paats39, Jorge Cieza Calderón40, Manuel Ugarte-Gil41, Armando Calvo42, Rodamin Ambiorix Alvarez Santana43, Analía Cánepa44, Carina Pizzarossa44, Federico Zazzetti45, Ashley Orillion46 and Cristina Drenkard47, 1Colombian Association of Rheumatology (ASOREUMA), Bogotá, Colombia; Hospital Universitario San Ignacio, Bogotá, Colombia, Bogotá, Colombia, 2Hospital Universitario San Ignacio, Bogotá, Colombia, Bogotá, Colombia, 3Facultad de Medicina, Pontificia Universidad Javeriana, Bogotá, Colombia; Departamento de Medicina Interna, Unidad de Reumatología, Hospital Universitario San Ignacio, Bogotá, Colombia, BOGOTA, Colombia, 4Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, Rosario, Argentina, 5Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, Buenos Aires, Argentina, 6Hospital Italiano de Córdoba, Córdoba, Argentina, Córdoba, Argentina, 7Hospital Córdoba y Sanatorio Allende, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba, Argentina, Cordoba, Argentina, 8Hospital Privado Universitario de Cordoba, Córdoba, Argentina, Córdoba, Argentina, 9Hospital San Martin de La Plata, La Plata, Argentina, La Plata, Argentina, 10Sanatorio Británico, Rosario, Argentina, Rosario, Argentina, 11Hospital Ángel C. Padilla, Tucumán, Argentina, Tucumán, Argentina, 12Hospital J.M Ramos Mejía, Buenos Aires, Argentina, Buenos Aires, 13Instituto de Investigaciones Médicas Alfredo Lanari, Universidad de Buenos Aires, Buenos Aires, Argentina, Buenos Aires, Argentina, 14CEMIC Centro de Educación Médica e Investigaciones Clínicas ‘‘Norberto Quirno,’’ Buenos Aires, Argentina, Buenos Aires, Argentina, 15Hospital Señor del Milagro Salta, Salta, Argentina, Salta, Argentina, 16Hospital General de Agudos Dr. Juan A. Fernández, Buenos Aires, Argentina, Buenos Aires, Argentina, 17Hospital das Clinicas da Universidade Federal de Goias, Goiania, Brazil, Goiania, Brazil, 18Hospital de Clínicas de Porto Alegre, Universidade Federal Do Rio Grande Do Sul, Porto Alegre, Brazil, PORTO ALEGRE, Rio Grande do Sul, Brazil, 19Universidad Federal de Pernambuco, Recife, Brazil, Recife, Brazil, 20Hospital Universitário Pedro Ernesto - Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, Rio de Janeiro, Brazil, 21Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, 22Escola Paulista de Medicina / Universidade federal de São Paulo (EPM / Unifesp), São Paulo, Brazil, São Paulo, Brazil, 23Hospital del Salvador Santiago de Chile, Santiago, Chile, Santiago, Chile, 24Facultad de Medicina y Ciencia, Universidad San Sebastián, Santiago, Chile, Santiago, Chile, 25Universidad Simón Bolívar, Barranquilla, Colombia y Clínica de la Costa, Barranquilla, Colombia, 26Clínica de la Costa y Universidad Simón Bolívar Barranquilla, Barranquilla, Colombia, Barranquilla, Colombia, 27Fundación Valle del Lili, Universidad Icesi, Cali, Colombia, Cali, Colombia, 28Facultad de Medicina, Universidad Nacional de Colombia; Hospital Universitario Fundación Santa Fe de Bogotá; Hospital Universitario Nacional de Colombia, Bogotá, Colombia, Bogotá, Colombia, 29Pontificia Universidad Javeriana de Cali, Cali, Colombia, Cali, Colombia, 30Universidad de Especialidades Espíritu Santo, Guayaquil, Ecuador, Guayaquil, Ecuador, 31Hospital de Especialidades Dr. Antonio Fraga Mouret, Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Mexico City, Mexico, Mexico City, Mexico, 32Hospital de Especialidades del Centro Médico Nacional SXXI, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico, Mexico City, Mexico, 33Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico City, Mexico, 34Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, Mexico City, Mexico, 35Centro de Estudios de Investigación Básica y Clínica, S.C., Guadalajara, Mexico, Guadalajara, Mexico, 36Facultad de Medicina de la Universidad Autónoma de San Luis Potosí y Hospital Central "Dr. Ignacio Morones Prieto," San Luis Potosi, Mexico, San Luis Potosi, Mexico, 37Universidad Autónoma de Nuevo León, Rheumatology Service, Hospital Universitario "Dr. José Eleuterio González", Monterrey, Nuevo León, México., MONTERREY, Mexico, 38Facultad de Ciencias Medicas, Universidad Nacional de Asunción, San Lorenzo, Paraguay, Asuncion, Paraguay, 39Facultad de Ciencias Medicas, Universidad Nacional de Asunción, San Lorenzo, Paraguay, Asunción, Paraguay, 40Hospital Nacional Edgardo Rebagliati Martins-EsSalud, Lima, Peru, Lima, Peru, 41Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru; Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, Lima, Peru, 42Hospital Nacional Cayetano Heredia Universidad Peruana Cayetano Heredia, Lima, Peru, Jesús María, Peru, 43Hospital Docente Padre Billini, Santo Domingo, Distrito Nacional, Dominican Republic, 44Hospital de Clínicas, Facultad de Medicina, UDELAR, Montevideo, Uruguay, Montevideo, Uruguay, 45Johnson & Johnson, Horsham, PA, USA, Ambler, PA, 46Johnson & Johnson, Spring House, PA, USA, Spring House, PA, 47Rollins School of Public Health, Emory University, Atlanta, Georgia, USA, Acworth, GA

    Background/Purpose: The concept of disease modification (DM) has been recently introduced to improve the long-term care of patients (pts) with SLE. DM is defined as…
  • Abstract Number: 1320 • ACR Convergence 2025

    Trends In Incidence and Risk factors For Incident Venous Thromboembolism in Patients with Rheumatoid Arthritis: A Population-Based Retrospective Cohort Study

    Noah Frechette1, Elena myasoedova1, Iqra Javed1, Roslin George1, Sara Achenbach2 and Cynthia Crowson3, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Rochester, 3Mayo Clinic, Stewartvillle, MN

    Background/Purpose: Venous thromboembolism (VTE) is more common in patients with rheumatoid arthritis (RA) and can present as deep vein thrombosis (DVT) or pulmonary embolism (PE).…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 112
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology